CSPC Pharmaceutical Group Limited (1093.HK)
| Previous close | 6.220 |
| Open | 6.250 |
| Bid | 6.480 x 0 |
| Ask | 6.490 x 0 |
| Day's range | 6.230 - 6.550 |
| 52-week range | 5.200 - 8.250 |
| Volume | |
| Avg. volume | 38,650,013 |
| Market cap | 77.087B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 12.23 |
| EPS (TTM) | 0.530 |
| Earnings date | 23 May 2024 - 27 May 2024 |
| Forward dividend & yield | 0.28 (4.50%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | 9.70 |
- Reuters
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
PR NewswireElevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Cli
- PR Newswire
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that an abstract featuring SYSA1801 (EO-3021) Phase 1 clinical data has been selected for a poster presentation and poster discussion at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago,
